Impact of Tibial Run Off on Clinical Outcome of Endovascular Therapy in Femoropopliteal Lesions (TALENT Study)
NCT ID: NCT04675632
Last Updated: 2025-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1200 participants
OBSERVATIONAL
2021-01-04
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Real-world Study to Evaluate the Primary Patency and Freedom From TLR of Endovascular Treatment in TOSAKA III In-stent Restenosis of Lower Extremity Femoropopliteal Artery.
NCT04801004
Predicting Procedural and Long-term Outcomes of Endovascular Revascularization for Lower Extremity Peripheral Artery Chronic Total Occlusions With Computed Tomographic Angiography
NCT03734549
The Efficacy of Endovascular Treatment in FPOD With TASC C and D Lesions
NCT04698304
A Prospective, Multicenter, Observational Study on the Treatment of Chronic Common Femoral Artery Bifurcation Occlusion
NCT05603546
Endovascular Management of Combined Common Femoral and Superficial Femoral Arteries Lesions
NCT05569369
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose is to evaluate the patency of the tibial run off through a prospective multicenter observational real world study, whether it has an impact on the therapeutic effect after endovascular treatment in femoral popliteal artery , and whether one-stage reconstruction of the tibial run off can improve the postoperative patency rate of endovascular treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The intervention group
the tibial run off would be treated through endovascular therapy
Endovascular Therapy
the most commonly used surgical options include: ordinary balloon dilatation, drug-coated balloon (DCB) dilatation and bare stent implantation.
the non-intervention group
the tibial run off would not be treated through endovascular therapy
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endovascular Therapy
the most commonly used surgical options include: ordinary balloon dilatation, drug-coated balloon (DCB) dilatation and bare stent implantation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
3\) Whether it is a primary femoral and popliteal artery disease or in-stent restenosis, patients who received endovascular recanalization successfully (Residual stenosis \<30% and no flow-limiting arterial dissection) can be enrolled in the group.
4\) For the patients with both lower limbs to be treated, both limbs can be selected into the group.
5\) Patients who failed the first treatment because the guide wire could not pass through the lesion can still be included in the group after successful endovascular interventional treatment.
6\) Patients who understand the purpose of this research, volunteer to participate in the experiment, sign an informed consent form and are willing to be followed up can be included in the experiment.
7\) For ipsilateral aortoiliac artery disease, patients with residual stenosis \<30% can also be included in the group after intravascular reconstruction.
Exclusion Criteria
4\) Limbs that have been treated with the femoral and popliteal artery bypass surgery.
5\) Patients who are known to be allergic or sensitive to contrast agents, heparin, aspirin (ASA), other anticoagulant or antiplatelet therapies, and/or paclitaxel.
6\) Patients with bleeding constitution. 7) Pregnant and lactating women. 8) Patients with a history of myocardial infarction or unstable angina within 3 months.
9\) Patients with a history of TIA or cerebral infarction within 3 months. 10) Patients with severe disease such as liver failure. 11) Patients with a life expectancy of less than 24 months. 12) Participating in other drug or device studies currently. 13) Patients with poor treatment compliance or deemed unsuitable for inclusion in the group by the researcher.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chengdu University of Traditional Chinese Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chunshui He
the director of the vascular surgery of Hospital of Chengdu University of Traditional Chinese Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Meng Ye, doctor
Role: PRINCIPAL_INVESTIGATOR
RenJi Hospital
Ziheng Wu, doctor
Role: PRINCIPAL_INVESTIGATOR
Zhejiang University
Lianrui Guo, doctor
Role: PRINCIPAL_INVESTIGATOR
Xuanwu Hospital, Beijing
Xin Fang, doctor
Role: PRINCIPAL_INVESTIGATOR
Hangzhou First People's hospital of Medical College of Zhejiang University
Hongfei Sang, doctor
Role: PRINCIPAL_INVESTIGATOR
Second Affiliated Hospital of Suzhou University
Zibo Feng, doctor
Role: PRINCIPAL_INVESTIGATOR
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Qiang Li, doctor
Role: PRINCIPAL_INVESTIGATOR
Qingdao Haici Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chunshuihe
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Liu Y, Wang Q, Wu Z, Fen Z, Guo L, Li Q, Fang X, Sang H, Dai Y, He C, Ye M. A prospective, multicenter, real-world observational study evaluating the impact of tibial runoff on clinical outcomes after endovascular therapy for femoropopliteal lesions: Research protocol. Front Cardiovasc Med. 2022 Nov 16;9:1035659. doi: 10.3389/fcvm.2022.1035659. eCollection 2022.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ChengduUTCMvs2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.